# Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT06555263** · PHASE2 · WITHDRAWN · sponsor: **Sutro Biopharma, Inc.**

## Conditions studied

- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer, Nonsmall Cell
- Lung Cancer Non-Small Cell Stage IIIB
- Lung Cancer Non-small Cell Stage IV
- Lung Cancer, Non-small Cell

## Interventions

- **DRUG:** Luveltamab tazevibulin

## Key facts

- **NCT ID:** NCT06555263
- **Lead sponsor:** Sutro Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-21
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated Early
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06555263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06555263, "Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06555263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*